

LAZANDA - (EQ 0.1MG BASE,EQ 0.4MG BASE,EQ 0.3MG BASE ; SPRAY,METERED)

Generic Name	FENTANYL CITRATE	Innovator	BTCP PHARMA
Dosage	EQ 0.1MG BASE,EQ 0.4MG BASE,EQ 0.3MG BASE ; SPRAY,METERED	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	LAZANDA is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.